Literature DB >> 9628799

Apoptosis and morphologic changes in drug-treated trabecular meshwork cells in vitro.

S A Sibayan1, M A Latina, M E Sherwood, T J Flotte, K White.   

Abstract

Using an in vitro culture system, we investigated whether bovine trabecular meshwork cells undergo apoptosis (programmed cell death) following exposure to anti-glaucoma medications (timolol, pilocarpine and epinephrine) and known inducers of apoptosis (5-fluorouracil, mitomycin-C and dexamethasone). Third to fifth passage bovine trabecular meshwork cells were grown to confluence and incubated for 1-12 days in growth media with timolol (1-1000 microM), pilocarpine (15-15,000 microM), epinephrine (5-5000 microM), 5-fluorouracil (10-100 micrograms ml-1), mitomycin-C (0.01-100 micrograms ml-1) and dexamethasone (0.01-100 microM). The cultures were evaluated for apoptosis by phase-contrast microscopy, transmission electron microscopy and in situ apoptosis labeling. 5-Fluorouracil (10-100 micrograms ml-1), mitomycin-C (0.1-100 micrograms ml-1) and epinephrine (500-5000 microM) induced apoptosis in a dose and time-dependent manner. Timolol, pilocarpine, and dexamethasone-treated specimens did not show evidence of apoptosis at any of the concentrations tested. Trabecular meshwork cells incubated in timolol (100-1000 microM) developed cytoplasmic granules, and specimens treated with pilocarpine (15,000 microM) developed cytoplasmic vacuoles. These granules and vacuoles have the appearance of secondary lysosomes. Dexamethasone-treated cells developed an increased number of mitochondria. This study suggests that the trabecular meshwork may undergo apoptosis following exposure to 5-fluorouracil, mitomycin-C and epinephrine. Timolol, pilocarpine and dexamethasone did not induce apoptosis. However, these drugs can incite characteristic morphologic changes in cultured trabecular meshwork cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9628799     DOI: 10.1006/exer.1997.0458

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  7 in total

1.  Effects of dexamethasone on human trabecular meshwork cells in vitro.

Authors:  Ashish Sharma; Alammaprabhu Jayaprakash Patil; Saffar Mansoor; Maria F Estrago-Franco; Vincent Raymond; Maria Cristina Kenney; Baruch D Kuppermann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-05-03       Impact factor: 3.117

2.  Effect of the cytostatic agent idarubicin on fibroblasts of the human Tenon's capsule compared with mitomycin C.

Authors:  C Heilmann; P Schönfeld; T Schlüter; R Bohnensack; W Behrens-Baumann
Journal:  Br J Ophthalmol       Date:  1999-08       Impact factor: 4.638

3.  Characterizing the metabolic profile of dexamethasone treated human trabecular meshwork cells.

Authors:  Kimberly Graybeal; Luis Sanchez; Chi Zhang; Linsey Stiles; Jie J Zheng
Journal:  Exp Eye Res       Date:  2021-12-09       Impact factor: 3.770

4.  In vitro effects of preserved and unpreserved antiglaucoma drugs on apoptotic marker expression by human trabecular cells.

Authors:  Pascale Hamard; Catherine Blondin; Caroline Debbasch; Jean-Michel Warnet; Christophe Baudouin; Françoise Brignole
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-11-07       Impact factor: 3.117

5.  Apoptosis of human trabecular meshwork cells induced by transforming growth factor-beta2 in vitro.

Authors:  Yang Cao; Houren Wei; Michael Pfaffl; Banghong Da; Zhongyu Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2004

6.  Apoptosis in the trabecular meshwork of glaucomatous patients.

Authors:  Jimena Baleriola; Julián García-Feijoo; José M Martínez-de-la-Casa; Arturo Fernández-Cruz; Enrique J de la Rosa; Raquel Fernández-Durango
Journal:  Mol Vis       Date:  2008-08-18       Impact factor: 2.367

7.  Effects of triamcinolone acetonide on human trabecular meshwork cells in vitro.

Authors:  Ashish Sharma; A Jayaprakash Patil; Navin Gupta; M F Estrago-Franco; Saffar Mansoor; Vincent Raymond; M Cristina Kenney; Baruch D Kuppermann
Journal:  Indian J Ophthalmol       Date:  2014-04       Impact factor: 1.848

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.